SG10201502566SA - Use of novel pan-cdk inhibitors for treating tumors - Google Patents

Use of novel pan-cdk inhibitors for treating tumors

Info

Publication number
SG10201502566SA
SG10201502566SA SG10201502566SA SG10201502566SA SG10201502566SA SG 10201502566S A SG10201502566S A SG 10201502566SA SG 10201502566S A SG10201502566S A SG 10201502566SA SG 10201502566S A SG10201502566S A SG 10201502566SA SG 10201502566S A SG10201502566S A SG 10201502566SA
Authority
SG
Singapore
Prior art keywords
treating tumors
cdk inhibitors
novel pan
pan
novel
Prior art date
Application number
SG10201502566SA
Other languages
English (en)
Inventor
Ulrich Lücking
Gerhard Siemeister
Antje Margret Wengner
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of SG10201502566SA publication Critical patent/SG10201502566SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG10201502566SA 2010-04-01 2011-03-28 Use of novel pan-cdk inhibitors for treating tumors SG10201502566SA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102010014426A DE102010014426A1 (de) 2010-04-01 2010-04-01 Verwendung neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren

Publications (1)

Publication Number Publication Date
SG10201502566SA true SG10201502566SA (en) 2015-05-28

Family

ID=43858236

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201502566SA SG10201502566SA (en) 2010-04-01 2011-03-28 Use of novel pan-cdk inhibitors for treating tumors
SG2012065819A SG183925A1 (en) 2010-04-01 2011-03-28 Use of novel pan-cdk inhibitors for treating tumors

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2012065819A SG183925A1 (en) 2010-04-01 2011-03-28 Use of novel pan-cdk inhibitors for treating tumors

Country Status (21)

Country Link
US (1) US20130210846A1 (cg-RX-API-DMAC7.html)
EP (1) EP2552450A1 (cg-RX-API-DMAC7.html)
JP (1) JP5816259B2 (cg-RX-API-DMAC7.html)
KR (1) KR20130014678A (cg-RX-API-DMAC7.html)
CN (1) CN102834100A (cg-RX-API-DMAC7.html)
AU (1) AU2011234654B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012024422A2 (cg-RX-API-DMAC7.html)
CA (1) CA2794996A1 (cg-RX-API-DMAC7.html)
CL (1) CL2012002753A1 (cg-RX-API-DMAC7.html)
CR (1) CR20120502A (cg-RX-API-DMAC7.html)
DE (1) DE102010014426A1 (cg-RX-API-DMAC7.html)
DO (1) DOP2012000260A (cg-RX-API-DMAC7.html)
EC (1) ECSP12012198A (cg-RX-API-DMAC7.html)
MA (1) MA34098B1 (cg-RX-API-DMAC7.html)
MX (1) MX337722B (cg-RX-API-DMAC7.html)
NZ (1) NZ602710A (cg-RX-API-DMAC7.html)
PH (1) PH12012501945A1 (cg-RX-API-DMAC7.html)
SG (2) SG10201502566SA (cg-RX-API-DMAC7.html)
TN (1) TN2012000469A1 (cg-RX-API-DMAC7.html)
UA (1) UA108494C2 (cg-RX-API-DMAC7.html)
WO (1) WO2011120922A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013234451A1 (en) * 2012-03-21 2014-09-25 Bayer Intellectual Property Gmbh Use of (RS)-S-cyclopropyl-S-(4-{[4-{[1R, 2R)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl] amino}phenyl)sulfoximide for treating specific tumours
HK1211229A1 (en) * 2013-03-07 2016-05-20 Bayer Pharma Aktiengesellschaft Use of (rs)-s-cyclopropyl-s-(4-{[4-{[(1r,2r)-2-hydroxy-1-methylpropyl]- oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide for treatment of specific tumours
PL2968294T3 (pl) * 2013-03-13 2019-10-31 Oncoceutics Inc 7-Benzylo-10-(2-metylobenzylo)-2,6,7,8,9,10-heksahydroimidazo[1,2-a]pirydo[4,3-d]pirymidyn-5(3H)-on do zastosowania w leczeniu nowotworu
WO2014173815A1 (en) * 2013-04-23 2014-10-30 Bayer Pharma Aktiengesellschaft Use of (rs)-s-cyclopropyl-s-(4-{[4-{[(1r, 2r)-2-hydroxy-1-methylpropyl]oxy}-5- (trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulphoximide for the treatment of specific tumours
WO2014202583A1 (en) * 2013-06-21 2014-12-24 Bayer Pharma Aktiengesellschaft Substituted benzylpyrazoles
WO2015071231A1 (de) * 2013-11-14 2015-05-21 Bayer Pharma Aktiengesellschaft Kombinationen von (rs)-s-cyclopropyl-s-(4-{[4-{[(1r, 2r)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluormethyl)pyrimidin-2-yl]amino}phenyl)sulfoximid zur behandlung von tumoren
CN109283263B (zh) * 2017-07-21 2019-06-25 南京正大天晴制药有限公司 用于雷替曲塞合成质量控制的检测分析方法
CN109283279B (zh) * 2017-07-21 2019-11-01 南京正大天晴制药有限公司 通过高效液相色谱法分离测定雷替曲塞及其对映异构体的方法
EP4251613A4 (en) * 2020-11-27 2024-11-20 Allorion Therapeutics Inc. AMINOHETEROARYL KINASE INHIBITORS

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4029650A1 (de) 1990-09-19 1992-03-26 Hoechst Ag 2-anilino-pyrimidine, verfahren zu ihrer herstellung, sie enthaltene mittel und ihre verwendung als fungizide
EP1017394B1 (en) 1997-07-12 2005-12-07 Cancer Research Technology Limited Cyclin dependent kinase inhibiting purine derivatives
US6440965B1 (en) 1997-10-15 2002-08-27 Krenitsky Pharmaceuticals, Inc. Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
ATE336484T1 (de) 1998-08-29 2006-09-15 Astrazeneca Ab Pyrimidine verbindungen
GB9824579D0 (en) * 1998-11-10 1999-01-06 Novartis Ag Organic compounds
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
IL159120A0 (en) 2001-05-29 2004-05-12 Schering Ag Cdk inhibiting pyrimidines, production thereof and their use as medicaments
JP2005526765A (ja) 2002-03-11 2005-09-08 シエーリング アクチエンゲゼルシャフト Cdk−阻害性2−ヘテロアリール−ピリミジン類、それらの生成及び医薬としての使用
DE10349423A1 (de) * 2003-10-16 2005-06-16 Schering Ag Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
DE102005062742A1 (de) * 2005-12-22 2007-06-28 Bayer Schering Pharma Ag Sulfoximin substituierte Pyrimidine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel
DE102006027156A1 (de) * 2006-06-08 2007-12-13 Bayer Schering Pharma Ag Sulfimide als Proteinkinaseinhibitoren
EP1878726A1 (en) * 2006-07-12 2008-01-16 Bayer Schering Pharma Aktiengesellschaft Substituted sulphoximines as Tie2 inhibitors and salts thereof, pharmaceutical compositions comprising the same, methods of preparing the same and uses of the same
EP2022785A1 (en) * 2007-06-20 2009-02-11 Bayer Schering Pharma Aktiengesellschaft Alkynylpyrimidines as Tie2 kinase inhibitors
WO2009100176A2 (en) * 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
EP2179991A1 (de) * 2008-10-21 2010-04-28 Bayer Schering Pharma Aktiengesellschaft Sulfoximinsubstituierte Anilino-Pyrimidinderivate als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel

Also Published As

Publication number Publication date
DE102010014426A1 (de) 2011-10-06
NZ602710A (en) 2014-05-30
CA2794996A1 (en) 2011-10-06
BR112012024422A2 (pt) 2016-05-31
AU2011234654A1 (en) 2012-10-25
MX2012011427A (es) 2013-03-05
AU2011234654B2 (en) 2015-08-06
MX337722B (es) 2016-03-16
PH12012501945A1 (en) 2017-08-09
JP2013523680A (ja) 2013-06-17
TN2012000469A1 (en) 2014-01-30
US20130210846A1 (en) 2013-08-15
WO2011120922A1 (de) 2011-10-06
CN102834100A (zh) 2012-12-19
CR20120502A (es) 2012-11-20
EP2552450A1 (de) 2013-02-06
KR20130014678A (ko) 2013-02-08
SG183925A1 (en) 2012-10-30
CL2012002753A1 (es) 2013-01-18
UA108494C2 (uk) 2015-05-12
JP5816259B2 (ja) 2015-11-18
ECSP12012198A (es) 2012-10-30
MA34098B1 (fr) 2013-03-05
DOP2012000260A (es) 2013-03-31

Similar Documents

Publication Publication Date Title
IL276362A (en) Cancer treatment methods
IL277579A (en) Piperidinone derivatives as MDM2 inhibitors for cancer therapy
IL232128B (en) Tor kinase inhibitors for cancer treatment
HUE060305T2 (hu) FAP-aktivált proteaszóma inhibitorok a szolid tumorok kezelésére
SI2523661T1 (sl) Nkcc inhibitorji za zdravljenje avtizma
IL215767A0 (en) Methods of treatment for solid tumors
ZA201206456B (en) Uses of dgati inhibitors
EP2643001A4 (en) METHOD OF TREATING CANCER
ZA201304226B (en) Methods of treating cancer
IL221404A (en) Inhibits thiogenethone-based autophagy based on cancer therapy
IL227972A0 (en) Use of glycopyrrolate to treat tachycardia
EP2665706A1 (en) Novel 4-amino-n-hydroxy-benzamides as hdac inhibitors for the treatment of cancer
EP2640390A4 (en) METHODS OF TREATING CANCER
GB201214877D0 (en) Compounds for treatments of tumors
WO2012037553A9 (en) Use of pkc-iota inhibitors for the treatment of breast cancer
IL215199A0 (en) Thia-triaza-cyclopentazulenes as pi3-kinases inhibitors for the treatment of cancer
IL231448A0 (en) Phosphatidylinositol 3-kinase inhibitors for cancer treatment
GB201019034D0 (en) Treatment for tumors